Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.45 +0.01 (+1.69%)
As of 06/5/2026 03:59 PM Eastern
Compare

MDNA vs. APM, GXE, CGC, WMD, and EQ

Should you buy Medicenna Therapeutics stock or one of its competitors? MarketBeat compares Medicenna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicenna Therapeutics include Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), WeedMD (WMD), and EQ (EQ). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to Andean Precious Metals?

Andean Precious Metals (CVE:APM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

13.2% of Andean Precious Metals shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 69.4% of Andean Precious Metals shares are owned by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Andean Precious Metals has a net margin of 16.17% compared to Medicenna Therapeutics' net margin of -533,640.00%. Andean Precious Metals' return on equity of 20.32% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Andean Precious Metals16.17% 20.32% 4.13%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Andean Precious Metals has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Andean Precious Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Andean Precious MetalsC$154.78M0.88C$37.41MC$0.512.55
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Andean Precious Metals. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Andean Precious Metals. Andean Precious Metals' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Andean Precious Metals Neutral
Medicenna Therapeutics Neutral

Andean Precious Metals has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.891195, indicating that its share price is 189% more volatile than the broader market.

Summary

Andean Precious Metals beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Gear Energy?

Medicenna Therapeutics (TSE:MDNA) and Gear Energy (TSE:GXE) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Gear Energy 5.77%3.52%4.84%

Medicenna Therapeutics has a beta of 2.891195, indicating that its share price is 189% more volatile than the broader market. Comparatively, Gear Energy has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market.

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 2.4% of Gear Energy shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 7.6% of Gear Energy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Gear Energy. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Gear Energy. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Gear Energy'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Gear Energy Neutral

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Medicenna Therapeutics (TSE:MDNA) and Canadian Gold (CVE:CGC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Medicenna Therapeutics has a beta of 2.891195, indicating that its share price is 189% more volatile than the broader market. Comparatively, Canadian Gold has a beta of -1.586234, indicating that its share price is 259% less volatile than the broader market.

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Canadian Gold shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 43.3% of Canadian Gold shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Canadian Gold N/A -92.98%-48.06%

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Canadian Gold. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Canadian Gold. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Canadian Gold'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Canadian Gold Neutral

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A

Summary

Medicenna Therapeutics and Canadian Gold tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

WeedMD (CVE:WMD) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
WeedMDN/A N/A N/A
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Medicenna Therapeutics has lower revenue, but higher earnings than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

In the previous week, Medicenna Therapeutics had 1 more articles in the media than WeedMD. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for WeedMD. WeedMD's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
WeedMD Neutral
Medicenna Therapeutics Neutral

Summary

WeedMD and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to EQ?

EQ (CVE:EQ) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

EQ has a beta of -0.095108, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.891195, suggesting that its share price is 189% more volatile than the broader market.

EQ has a net margin of -11.73% compared to Medicenna Therapeutics' net margin of -533,640.00%. EQ's return on equity of 50.96% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
EQ-11.73% 50.96% -18.43%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

EQ has higher revenue and earnings than Medicenna Therapeutics. EQ is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EQC$10.54M6.34-C$4.66M-C$0.02N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

0.1% of EQ shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 12.8% of EQ shares are held by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, EQ had 3 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 4 mentions for EQ and 1 mentions for Medicenna Therapeutics. EQ's average media sentiment score of 0.55 beat Medicenna Therapeutics' score of 0.00 indicating that EQ is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EQ
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medicenna Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

EQ beats Medicenna Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$36.91MC$460.16MC$6.66BC$12.98B
Dividend YieldN/A3.87%2.67%6.20%
P/E Ratio-3.003.1524.0336.71
Price / SalesN/A6,626.88514.2610.53
Price / Cash1.1513.1326.9982.29
Price / Book6.0483.4710.244.41
Net Income-C$25.98M-C$96.07MC$3.57BC$299.09M
7 Day Performance5.88%-2.00%-1.28%-2.47%
1 Month Performance-23.73%1.08%1.38%-1.45%
1 Year Performance-50.55%64.32%23.93%44.27%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.45
+1.7%		N/A-50.5%C$36.91MN/AN/A20
APM
Andean Precious Metals
N/AC$1.29
+7.5%		N/A+0.0%C$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/A+118.2%C$126.35MN/AN/A3,150
WMD
WeedMD
N/AC$0.28
-1.8%		N/A+0.0%C$67.82MC$27.53MN/A628

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel